Geneva, Switzerland and Boston, MA – June 29, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Month: June 2020
ObsEva Annual General Meeting 2020
Tuesday, June 9, 2020 at 10:30 a.m. CET Location: ObsEva offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates,…
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020
Geneva, Switzerland and Boston, MA – June 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company…
ObsEva Annual General Meeting 2020: Tuesday June 9, 2020
Tuesday, June 9, 2020 at 10:30 a.m. CET Location: ObsEva offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates,…
Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Jacques Donnez, M.D., Ph.D., Hugh S. Taylor, M.D., Ph.D., Robert N. Taylor, M.D., Ph.D., Mark D. Akin, M.D., Tatyana F. Tatarchuk, M.D., Dr. Sc., Krzysztof Wilk, M.D., Jean-Pierre Gotteland, Ph.D., Veronique Lecomte, Pharm.D., Elke Bestel, M.D.
Published online: June 03, 2020
Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and…
ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020
Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis
Olivier Donnez M.D., Ph.D. , Jacques Donnez M.D., Ph.D.
Published online: June 02, 2020